Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.67 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | PPARA | Q07869 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | MMP12 | P39900 | 1/20 | 0.46 |
| ▸ | MMP13 | P45452 | 1/20 | 0.46 |
| ▸ | THRA | P10827 | 2/20 | 0.46 |
| ▸ | THRB | P10828 | 2/20 | 0.46 |
| ▸ | RARB | P10826 | 2/20 | 0.46 |
| ▸ | PLK1 | P53350 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methane SCHEMBL10448934 | 0.98 | HSD17B10 (0.65) | HSD17B10CYP4A11KMT2ACYP4F2LMNA | |
| SCHEMBL9253738 | 0.94 | CYP4A11 (0.66) | HSD17B10CYP4A11KMT2ACYP4F2LMNA | |
| SCHEMBL28560062 | 0.92 | CYP4A11 (0.64) | HSD17B10CYP4A11KMT2ACYP4F2LMNA | |
| SCHEMBL7741661 | 0.92 | CYP4A11 (0.64) | HSD17B10CYP4A11KMT2ACYP4F2LMNA | |
| SCHEMBL9445340 | 0.92 | CYP4A11 (0.64) | HSD17B10CYP4A11KMT2ACYP4F2LMNA | |
| SCHEMBL11424105 | 0.89 | HSD17B10 (0.74) | HSD17B10CYP4A11KMT2ACYP4F2LMNA | |
| SCHEMBL17457887 | 0.89 | HSD17B10 (0.74) | HSD17B10CYP4A11KMT2ACYP4F2LMNA | |
| SCHEMBL8363903 | 0.89 | CYP4A11 (0.60) | HSD17B10CYP4A11KMT2ACYP4F2LMNA | |
| SCHEMBL8362682 | 0.89 | CYP4A11 (0.60) | HSD17B10CYP4A11KMT2ACYP4F2LMNA | |
| SCHEMBL8362472 | 0.87 | CYP4A11 (0.58) | HSD17B10CYP4A11KMT2ACYP4F2CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230331681-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2023-10-19 | — | — | US | disclosed |
| WO-2023093728-A1 | BRM SELECTIVE DEGRADATION AGENT COMPOUND AND USE THEREOF | 江苏先声药业有限公司 | 2023-06-01 | — | — | WO | disclosed |
| WO-2023093728-A1 | BRM SELECTIVE DEGRADATION AGENT COMPOUND AND USE THEREOF | 江苏先声药业有限公司 | 2023-06-01 | — | — | WO | disclosed |
| US-5385693-A | Having rapid response and low phase transition temperature | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1995-01-31 | — | — | US | disclosed |
| EP-0357372-B1 | Optically active ester derivatives, preparation process thereof, liquid crystal materials and a light switching element | SUMITOMO CHEMICAL CO (JP) | 1994-11-17 | — | — | EP | disclosed |
| US-5264151-A | Optically active ester derivatives, preparation process thereof, liquid crystal materials and a light switching element | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1993-11-23 | — | — | US | disclosed |
| US-5124070-A | High speed response | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1992-06-23 | — | — | US | disclosed |
| EP-0395697-A4 | QUINOLINE DERIVATIVES AS ANTAGONISTS OF LEUKOTRIENE D 4? | — | 1991-03-13 | — | — | EP | disclosed |
| EP-0395697-A1 | QUINOLINE DERIVATIVES AS ANTAGONISTS OF LEUKOTRIENE D 4 | RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) | 1990-11-07 | — | — | EP | disclosed |
| US-4920133-A | Quinoline derivatives and use thereof as antagonists of leukotriene D4 | RORER PHARMACEUTICAL CORP. (US) | 1990-04-24 | — | — | US | disclosed |
| EP-0357372-A2 | Optically active ester derivatives, preparation process thereof, liquid crystal materials and a light switching element | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1990-03-07 | — | — | EP | disclosed |
| WO-1989004303-A1 | QUINOLINE DERIVATIVES AS ANTAGONISTS OF LEUKOTRIENE D4 | RORER INTERNATIONAL (OVERSEAS) INC. (US) | 1989-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230331681-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, ADRM1, CRBN | HSD17B10 332/4885CYP4A11 553/4885KMT2A 1463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.